SCHEMBL6568030

SCHEMBL6568030

COCOc1ccc(C(=O)O)cc1OC

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.73
CA12 O43570 1/20 0.71
CA1 P00915 1/20 0.71
CA2 P00918 1/20 0.71
CA4 P22748 1/20 0.71
CA6 P23280 1/20 0.71
CA7 P43166 1/20 0.71
TPMT P51580 1/20 0.71
CA9 Q16790 1/20 0.71
CA14 Q9ULX7 1/20 0.71
MRGPRX4 Q96LA9 1/20 0.61
TTR P02766 2/20 0.58
HTT P42858 3/20 0.57
MAPK1 P28482 2/20 0.56
LMNA P02545 2/20 0.56
RAB9A P51151 1/20 0.56
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
PLA2G4B P0C869 1/20 0.53
CYP1A2 P05177 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3046092 0.93 CA12 (0.71) TSHRCA12CA1CA2CA4
SCHEMBL3480035 0.93 TSHR (0.63) TSHRCA12CA1CA2CA4
SCHEMBL3480458 0.92 TSHR (0.61) TSHRCA12CA1CA2CA4
SCHEMBL2848020 0.87 KMT2A (0.61) TSHRCA12CA1CA2CA4
SCHEMBL8122418 0.86 TSHR (0.78) TSHRCA12CA1CA2CA4
SCHEMBL8085474 0.86 TSHR (0.78) TSHRCA12CA1CA2CA4
SCHEMBL6564723 0.86 TSHR (0.77) TSHRCA12CA1CA2CA4
SCHEMBL18456830 0.85 MAPT (0.64) TSHRCA12CA1CA2CA4
SCHEMBL6939685 0.85 TSHR (0.71) TSHRCA12CA1CA2CA4
SCHEMBL566581 0.85 TSHR (1.00) TSHRCA12CA1CA2CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250051296-A1 MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2025-02-13 US disclosed
US-12103917-B2 Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2024-10-01 US disclosed
US-20210300882-A1 MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF Sanford Burnham Prebys Medical Discovery Institute (US) 2021-09-30 US disclosed
US-20210300882-A1 MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF Sanford Burnham Prebys Medical Discovery Institute (US) 2021-09-30 US disclosed
US-11028061-B2 Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof Sanford Burnham Prebys Medical Discovery Institute (US) 2021-06-08 US disclosed
US-11028061-B2 Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof Sanford Burnham Prebys Medical Discovery Institute (US) 2021-06-08 US disclosed
US-20180222874-A1 MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF Sanford Bumham Prebys Medical Discovery Imstitute (US) 2018-08-09 US disclosed
US-20180222874-A1 MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF Sanford Bumham Prebys Medical Discovery Imstitute (US) 2018-08-09 US disclosed
US-20180222874-A1 MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF Sanford Bumham Prebys Medical Discovery Imstitute (US) 2018-08-09 US disclosed
WO-2017019772-A1 MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF Sanford Burnham Prebys Medical Discovery Institute (US) 2017-02-02 WO disclosed
WO-2017019772-A1 MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF Sanford Burnham Prebys Medical Discovery Institute (US) 2017-02-02 WO disclosed
US-20040259912-A1 Benzine derivatives, process for preparing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-12-23 US disclosed
EP-1437344-A1 BENZENE DERIVATIVES,PROCESS FOR PREPARING THE SAME AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2004-07-14 EP disclosed
US-5914406-A ENZYME INHIBITOR; USEFUL FOR TREATMENT OF INFLAMMATORY SKIN DISORDERS AND ALOPECIA HOFFMAN-LA ROCHE INC. (US) 1999-06-22 US disclosed
US-5750706-A TREATMENT OF INFLAMMATORY SKIN DISORDERS AND ALOPECIA HOFFMANN-LA ROCHE INC. (US) 1998-05-12 US disclosed
US-5583222-A ANTIINFLAMMATORY AGENTS FOR TREATMENT OF SKIN DISORDERS HOFFMANN-LA ROCHE INC. (US) 1996-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250051296-A1 MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF MYC, MYCBP, MLYCD TSHR 1385/4885CA12 4112/4885CA1 2894/4885
US-20210300882-A1 MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF MYC, MYCBP, MLYCD TSHR 1385/4885CA12 4112/4885CA1 2894/4885
US-20180222874-A1 MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF MYC, MYCBP, MLYCD TSHR 1385/4885CA12 4112/4885CA1 2894/4885
US-11028061-B2 Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof MYC, MYCBP, MLYCD TSHR 1385/4885CA12 4112/4885CA1 2894/4885
US-12103917-B2 Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof MYC, MYCBP, MLYCD TSHR 1385/4885CA12 4112/4885CA1 2894/4885
US-20040259912-A1 Benzine derivatives, process for preparing the same and use thereof HRH4, HRH2, HRH1 TSHR 1061/4885CA12 4703/4885CA1 3612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.